Sinopharm vaccine has been found to be effective in boys aged 3 to 17, trial found

The test randomized, double-blind and controlled, phase 1 and 2, was carried out by stratifying healthy volunteers in age.

Precisely the Sinopharm vaccine is the one that Argentina has the most, thanks to a contract signed months ago with the Chinese state laboratory that produces it. So far it has received 22.9 million doses, while Sputnik has added 17.1 million and AstraZeneca 16.1 million.

But this Saturday, a new shipment with more than 1.5 million doses of Sinopharm was added to the vaccination plan via a flight that arrived in Ezeiza at 6.30 p.m. Another shipment, consisting of 1.3 million, will arrive at 7 a.m. on Monday.

The two shipments will allow the government to “step up” vaccination across the country, exceeding the 63 million vaccines received since the start of the vaccination plan.

Argentina also received 3.5 million Moderna vaccines donated by the United States, 400,000 from Cansino and 260,910 from Pfizer.

In the Sinopharm children’s lawsuit, the The researchers divided into three groups, which received different doses of immunization: three to five years old, six to 12 years old and 13 to 17 years old.

According to the researchers, the doses were administered with 28 days of separation. 445 boys participated in phase 1, while 810 children were selected for phase 2.

Regarding safety, scientists have assured that the undesirable effect the most common was the pain at the injection site, Followed by fever. In most cases, the severity of these effects “was mild to moderate” and they were “transient or resolved within days”.